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Summary The methyl-thiazol-tetrazolium (MTU) assay is a drug resistance assay which cannot discriminate
between malignant and non-malignant cells. We previously reported that samples with > 80% leukaemic cells
at the start of culture give similar results in the MTT assay and the differential staining cytotoxicity assay, in
which a discrimination between malignant and non-malignant cells can be made. However, the percentage of
leukaemic cells may change during culture, which might affect the results of the MTT assay. We studied 106
untreated childhood acute lymphoblastic leukaemia (ALL) samples with > 80% leukaemic cells at the start of
culture. This percentage decreased below 80% in 28%, and below 70% in 13%, of the samples after 4 days of
culture. A decrease below 70% occurred more often in case of 80-89% leukaemic cells (9/29) than in case of
> 90% leukaemic cells at the start of culture (5/77, P = 0.0009). Samples with <70% leukaemic cells after
culture were significantly more resistant to 6 out of 13 drugs, and showed a trend towards being more resistant
to two more drugs, than samples with > 80% leukaemic cells. No such differences were seen between samples
with 70-79% and samples with > 80% leukaemic cells after culture. We next studied in another 30 ALL
samples whether contaminating mononuclear cells could be removed by using immunomagnetic beads. Using a
beads to target cell ratio of 10:1, the percentage of leukaemic cells increased from mean 72% (s.d. 9.3%) to
mean 87% (s.d. 6.7%), with an absolute increase of 2-35%. The recovery of leukaemic cells was mean 82.1%
(range 56-100%, s.d. 14.0%). The procedure itself did not influence the results of the MTT assay in three
samples containing only leukaemic cells. We conclude that it is important to determine the percentage of
leukaemic cells at the start and at the end of the MTT assay and similar drug resistance assays. Contaminating
mononuclear cells can be successfully removed from ALL samples using immunomagnetic beads. This
approach may increase the number of leukaemic samples which can be evaluated for cellular drug resistance
with the MTT assay or a similar cell culture drug resistance assay.
The methyl-thiazol-tetrazolium (MTT) assay is a short-term
cell culture drug resistance assay. It is based on the fact that
living cells, in contrast to dead cells, can reduce MTT to a
coloured formazan product, which is measured spectro-
photometrically. The principle was described in 1953 by
Black and Speer, while Mosmann described the MTT assay
in 1983 in its present semiautomated form. It is a rapid,
reliable and objective assay, suited for large-scale patient
studies in leukaemia and lymphoma (Veerman & Pieters,
1990). Therefore, this assay was adapted for drug resistance
testing of human leukaemia samples (Hongo et al., 1987;
Campling et al., 1988; Pieters et al., 1988; Sargent & Taylor,
1989; Twentyman et al., 1989; Hwang et al., 1993). The
results of this and other tetrazolium salt (e.g. INT)-based
cellular drug resistance assays correlate well with the clinical
outcome after chemotherapy (Santini et al., 1989; Sargent &
Taylor, 1989; Hongo et al., 1990; Pieters et al., 1991; Kaspers
et al., 1993a,b).
A disadvantage of the MTT assay, and of other assays
such as the fluorometric microculture cytotoxicity assay
(Larsson et al., 1992) and the INT assay (Santini et al.,
1989), is that no discrimination can be made between malig-
nant and non-malignant living cells. Such a discrimination
can be made with the differential staining cytotoxicity (DiSC)
assay (Weisenthal & Kern, 1991), but this assay is laborious
and subjective (Veerman & Pieters, 1990). An alternative may
be the removal of contaminating mononuclear cells from
malignant samples.
We previously reported that normal peripheral blood lym-
phocytes are more resistant to drugs than untreated child-
hood acute lymphoblastic leukaemia (ALL) samples (Kaspers
et al., 1991). Therefore, the presence of these cells in an ALL
sample will influence the MTT assay results. It has been
shown that when 80% or more leukaemic cells are present in
the sample at the start of the assay, the MTT assay and
DiSC assay provide similar results (Pieters et al., 1989; Kirk-
patrick et al., 1990). However, one should also consider the
percentage of leukaemic cells after culture, because a decrease
in this percentage may influence the assay results.
We studied in 106 untreated childhood ALL samples
whether a decrease in the percentage of leukaemic cells had
occurred after culture, and whether this influenced the drug
resistance profile. We also investigated in another group of
untreated or relapsed ALL samples whether contaminating
mononuclear cells could be removed by using immuno-
magnetic Dynabeads. This may increase the number of sam-
ples which can be evaluated for cellular drug resistance using
the MTT assay or similar drug resistance assays.
Materials and methods
Cells
Mononuclear cells were isolated from the bone marrow or
peripheral blood samples by Ficoll density-gradient cen-
trifugation (Ficol Paque; density 1.077g ml-'; Pharmacia,
Sweden) for 15 min (room temperature, 1,000g), washed
twice, and resuspended in RPMI-1640 (Dutch modification,
Gibco, Uxbridge, UK). The medium contained 20% fetal calf
serum (Flow Laboratories, Irvine, UK) and several other
supplements (Pieters et al., 1990).
A total of 106 samples from children with newly diagnosed
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ALL with > 80% leukaemic cells were used to study changes
in the percentage of leukaemic cells before and after culture
and to study the possible influence of such changes on the
results of cellular drug resistance testing. The percentage of
leukaemic cells was determined morphologically. In case of
any doubt, different technicians determined the percentage
independently and immunology was used whenever possible.
The samples consisted of 80 cases of precursor B-ALL
[positive for terminal deoxynucleotidyl-transferase (TdT),
HLA-DR and CD19), 25 cases of T-ALL (positive for TdT,
cytoplasmic CD3 and CD7), and one case with unknown
immunophenotype. Precursor B-ALL was subdivided into
pro-B-ALL [CD10-, cytoplasmic fi chain (cg)-, n = 6], com-
mon ALL (CD10+, cri, n = 52) and pre-B ALL (cp+,
n = 22). The majority of these samples had been sent to the
research laboratory for paediatric haemato-onco-immunology
of the Free University Hospital of Amsterdam by the
laboratory of the Dutch Childhood Leukaemia Study Group
for cellular drug resistance testing.
Another group of 17 samples from children with newly
diagnosed ALL and 13 samples from children with relapsed
ALL was used to study the removal of mononuclear cells by
immunomagnetic beads and the influence of this procedure
on the results of cellular drug resistance testing. Most of
these samples were tested after cryopreservation.
Cell culture drug resistance assay
We used the colorimetric MTT assay, as described previously
(Pieters et al., 1990). Briefly, ALL cells were cultured in the
wells of microculture plates for 4 days at a final concentra-
tion of 1.2-1.6 x 106 cells ml-', with or without cytotoxic
agents. The 106 untreated childhood ALL samples were
tested with up to 13 drugs, depending on the number of cells
available: prednisolone (concentration range 0.05-1,500fig ml-'), dexamethasone (0.0002-6Lgml-'), vincristine (VCR,
0.05-501gml1'), vindesine (0.05-50fLgml'), daunorubicin
(0.002-2 ig ml-'), doxorubicin (0.008-8 tg ml-l), mitoxan-
trone (0.00l-ljgm11'), L-asparaginase (0.003-10IUml-'),
mercaptopurine (6MP, 15.6-500 gm1'I), thioguanine
(1.56-50 tgm1mP), teniposide (TEN, 0.003-81agmlm'), cyta-
rabine (ara-C, 0.002-2.5fgml-') and 4-hydroperoxyifos-
famide (4-HOO-ifosfamide, 0.1-100ggml-'). The samples
used for the experiments with the immunomagnetic beads
were usually tested with only 4-5 drugs, because of the lack
of material. Most drugs were obtained from the hospital
pharmacy, except that 6MP, thioguanine and doxorubicin
were from Sigma (St Louis, MO, USA) and 4-HOO-
ifosfamide was a gift from ASTA Pharma (Dr M. Peukert,
Bielefeld, Germany). After the incubation period, MTT
(Sigma) was added to all wells and the plates were again
incubated for 6 h. The formed formazan crystals were dis-
solved with acidified (0.04 N hydrochloric acid) isopropanol,
and the optical density in each well was measured with an
EL-312 microplate reader (Biotek Instruments, Winooski,
USA) at 562 nm. After correction for the optical density of
the medium, leukaemic cell survival (LCS) was calculated by
the equation: LCS = (OD treated well/mean OD control
wells) x 100%. The LC50, the concentration lethal to 50% of
the cells, was calculated from the dose-response curve and
used as measure for drug resistance.
Removal ofmononuclear cells using immunomagnetic
Dynabeads
The magnetic polystyrene beads (Dynabeads M-450, Dynal,
Norway) were washed twice in culture medium before use.
The immunophenotype of the leukaemia sample and the type
of contaminating mononuclear cells as identified mor-
phologically (mainly lymphocytes, and sometimes monocytes,
erythroblasts or immature myeloid cells) determined which
one of two protocols was used.
The first protocol was used in case of non-T-ALL con-
taminated by normal T lymphocytes, which constituted the
majority (19/30) of samples. The mononuclear cells isolated
after gradient centrifugation were incubated for 30min at
room temperature, with continuous gentle mixing, with the
monoclonal antibody CD2 directly coated on immuno-
magnetic Dynabeads to remove these T lymphocytes.
The second protocol was used in the other samples, i.e. in
case of non-T-ALL and T-ALL with contaminating
mononuclear cells other than T lymphocytes. We did not
encounter the problem of a T-ALL contaminated by normal
T lymphocytes. In this second protocol, the mononuclear
cells were first incubated for 30min at 37°C with one or
more of several mouse monoclonal antibodies, then washed
twice with protein-buffered saline and 0.1% bovine serum
albumin to remove unbound antibody, and after that
incubated for 30 min at room temperature with continuous
gentle mixing with Dynabeads coated with sheep anti-mouse
immunoglobulin G. The choice ofantibodies, used at concen-
trations as normally used in our laboratory for immunostain-
ing, depended on the type of contaminating mononuclear
cells: CD14 in the case of monocytes, CD15 in the case of
myeloid cells (CD15 plus CD13 if immature myeloid cells
were also present) and E-1 antigen in the case of erythroid
cells (E-1 plus H1-antigen if immature erythroid cells were
also present).
With both protocols, the tubes containing cells and
Dynabeads were placed on a magnet for 2 min. This resulted
in an adhesion of the target cells attached to the magnetic
beads to the wall of the tubes. The suspension was aspirated
and used for further studies. We used a beads to target cell
(cells to be removed) ratio of 10:1. This ratio was chosen
after preliminary experiments which showed that this was
optimal with respect to cell loss, enrichment and costs. The
effect of the Dynabeads procedure was assessed by compar-
ing the percentage of leukaemia cells, determined mor-
phologically, before and after the procedure.
Statistics
The Spearmans rank correlation test (parameter p) was used
to assess the correlation between several continuous
variables. The chi-squared test and Mann-Whitney U- or
Wilcoxon test for paired and unpaired samples were used for
two-tailed testing at a level of significance of 0.05. A P-value
of >0.05 and < 0.10 was considered to indicate a trend.
Results
Changes in percentage ofleukaemic cells
In the group of 106 untreated childhood ALL samples, the
median percentage of leukaemic cells was 93% (range
80-100%) before and 90% (range 7-99%) after the 4 days
of culture. There was a significant correlation between these
percentages (p=0.61, P<0.000001), as shown in Figure 1.
The percentage of leukaemic cells decreased below 80% in
28%, and below 70% in 13%, of the samples after 4 days of
culture (Table I). The number of cases with a decrease in the
percentage of leukaemic cells below 70% was higher
(P= 0.0009) in the case of 80-89% of leukaemic cells before
the start of culture (9/29 cases, 31%), than in the case of
90% leukaemic cells at that time (5/77 cases, 6%). There was
no significant relation between the occurrence of a decrease
below 70% leukaemic cells and sex, age, white blood cell
count at diagnosis, leukaemic cell burden, morphological
FAB type, or with sample source (bone marrow or peripheral
blood). This decrease below 70% occurred in two out of six
pro-B, seven out of 52 common ALL, one out of 22 pre-B
ALL and four out of 25 T-ALL, which was also not
significantly different (P = 0.30).
Percentage ofleukaemic cells and drug resistanceprofile
There was a significant correlation between the percentage of
leukaemic blast cells after 4 days of culture and LC^O values
for nine out of 13 drugs in the group of 106 untreated ALLMONONUCLEAR CELLS CONTAMINATING LEUKAEMIC SAMPLES TESTED FOR DRUG RESISTANCE 1049
samples. All of these correlations were negative, and p values
ranged from - 0.22 to - 0.35. Thus, lower percentages of
leukaemic blast cells were associated with higher LC50 values
(i.e. a more resistant MTT assay result). No significant cor-
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Figure I Percentage of ALL cells before and after 4 days of
culture in 106 untreated childhood ALL samples. The line shows
the cut-off level (70%) below which we consider the results for
samples not evaluable when the MTT assay is used.
Table I Change in percentage of leukaemic cells over the 4 day
culture period in 106 untreated childhood ALL samples
Per cent at day 0 n Per cent at day 4 n
80-84 12 <70 4 (33%)
70-79 5 (42%)
> 80 3 (25%)
85-89 17 <70 5 (29%)
70-79 4 (24%)
> 80 8 (47%)
90-94 42 <70 5 (12%)
70-79 4 (10%)
) 80 33 (78%)
95 35 <70 0
70-79 3 (9%)
80 32(91%)
relation was found for VCR, 6MP, ara-C or 4-HOO-
ifosfamide. The 106 samples were divided into three groups:
14 samples with <70%, 16 samples with 70-79% and 76
samples with > 80% leukaemic cells after culture. Table II
shows median LCm values and ranges for all 13 drugs for
these three groups. In general, samples with lower percen-
tages of leukaemic cells showed higher LC50 values. LC50
values for samples with 70-79% leukaemic cells and those
for samples with > 80% leukaemic cells after culture did not
differ at statistical analysis (Table II). Differences were also
not significant between samples with 70-79% leukaemic cells
and samples with > 90% leukaemic cells after culture (data
not shown). However, samples with <70% leukaemic cells
were significantly more resistant, or showed a trend towards
being more resistant to all drugs except VCR, 6MP, ara-C,
TEN and 4-HOO-ifosfamide, than samples with > 80%
leukaemic cells after culture (Table II).
There was no significant relation (Mann-Whitney U-test)
between treatment outcome and cell viability (P= 0.67) or
MTT-specific activity (MTT dye reduction capacity,
P= 0.82). The relation between drug resistance profiles and
treatment outcome will be the subject of another report.
There was also no correlation between cell viability or MTT-
specific activity with in vitro drug resistance (data not
shown).
Removal ofmononuclear cells using immunomagnetic
Dynabeads
The influence of this procedure on the results of the MTT
assay was studied in three ALL samples with > 95%
leukaemic cells after isolation. Each sample was divided in
two; one half was exposed to Dynabeads as described above
and one half was not. For all three samples, dose-response
curves for the four drugs tested were very similar for the
ALL cells which had been exposed and those which had not
been exposed to Dynabeads. This is illustrated in Figure 2
for one of these patients. In addition, the procedure did not
change the optical density of control wells (cells, no drugs),
and was not cytotoxic to the ALL cells as determined by
trypan blue exclusion.
Table II Relation between percentage of leukaemic cells at day 4 of culture and drug resistance
determined with the MTT assay in untreated childhood ALL
LC50 values in sgml-', median (range)
Group I Group 2 Group 3 P-values?
< 70% 70-79% > 80%
Drug (n = 14) (n = 16) (n = 76) 1 vs 2 1 vs 3 2 vs 3
Prednisolone 1500 2.20 1.03 0.0005 0.0001 0.60
(23.4-1500) (0.06-1500) (0.05-1500)
Dexamethasone 6 0.33 0.09 0.01 0.0001 0.66
(0.01-6) (0.01-6) (0.002-6)
Vincristine 5.55 0.68 0.71 0.14 0.26 0.59
(0.11-50) (0.07-28.2) (0.05-50)
Vindesine 13.87 2.64 2.47 0.13 0.06 0.97
(0.65-50) (0.53-34.2) (0.05-50)
Daunorubicin 0.34 0.21 0.12 0.20 0.02 0.39
(0.08-2) (0.06-0.88) (0.002-2)
Doxorubicin 0.57 0.44 0.40 0.16 0.08 0.83
(0.22-8) (0.17-1.33) (0.03-8)
Mitoxantrone 0.17 0.10 0.06 0.15 0.03 0.49
(0.04-1) (0.01-0.65) (0.001 -1)
L-Asparaginase 4.46 0.39 0.31 0.02 0.04 0.98
(IUml-') (0.003-10) (0.002- 1.88) (0.002-10)
Mercaptopurine 162.5 59.5 101.6 0.05 0.29 0.12
(22.7-500) (15.6-500) (15.6-500)
Thioguanine 13.0 7.3 6.4 0.04 0.02 0.72
(3.3-50) (1.8-12.2) (1.56-35.6)
Teniposide 1.30 0.32 0.30 0.34 0.14 0.48
(0.19-8) (0.20-1.45) (0.06-8)
Cytarabine 0.43 0.21 0.41 0.41 0.88 0.16
(0.03-2.5) (0.04-1.65) (0.002-2.5)
4-HOO-Ifosfamide 4.56 3.35 3.84 0.18 0.68 0.14
(0.27-23.56) (0.78-5.35) (0.79-20.3)
aMann-Whitney U-test for unpaired samples.
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Table III Results of removal of contaminating mononuclear cells
from 30 ALL samples using immunomagnetic beads
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Figure 2 Influence of the exposure ofimmunomagnetic beads on
cellular drug resistance in an ALL sample containing only
leukaemic cells before and after culture. Drug concentrations
increase from A to F (Materials and methods). Dose-response
curves are unchanged. a, -O-, Prednisolone, no beads; --0--,
prednisolone, after beads; -*-, asparaginase, no beads, *--,
asparaginase, after beads. b, -0-, Daunorubicin, no beads;
--O--, daunorubicin, after beads; -*-, vincristine, no beads;
vincristine, after beads.
Increase in percentage of leukaemic cells
Mean ± s.d.
Median (range)
Recovery of leukaemic cells (%)
Mean ± s.d.
Median (range)
Change in percentage of trypan blue-
positive cells
Mean ± s.d.
Median (range)
Cell survival after 4 days of culture (%)
Mean ± s.d.
Median (range)
Percentage of leukaemic cells after 4 days
of culture
Mean ± s.d.
Median (range)
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15.3 ± 8.4%
16% (2-35%)
82.1 ± 14.0%
80% (56-100%)
-3.7 ± 6.7
0% (-13- +8%)
54.8 ± 18.4%
56% (20-100%)
74.5 + 27.5%
86% (10-98%)
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The removal of mononuclear cells contaminating
leukaemic samples was tried in an additional 30 ALL sam-
ples, and the results are shown in Table III. The percentage
of leukaemic cells increased from mean 72.0% (s.d. 9.3%)
before to mean 87.0% (s.d. 6.7%) leukaemic cells after the
Dynabeads procedure. In 17 (77%) out of 22 samples with
<80% leukaemic cells, this percentage increased to > 80%
after removal of mononuclear cells. The recovery of
leukaemic cells was mean 82.1% (s.d. 14.0%, range
56- 100%). There was no correlation between the recovery of
leukaemic cells with the total cell number exposed to
Dynabeads (p = 0.06, P = 0.79) or with the percentage of
leukaemic cells in the sample before the exposure to
Dynabeads (p = 0.07, P = 0.77). The percentage of trypan
blue-positive dead cells decreased from mean 12.5% (s.d.
15.1%) before to mean 7.4% (s.d. 9.8%) after the Dynabeads
exposure.
Whether the removal of mononuclear cells from ALL sam-
ples actually resulted in a change in drug resistance
profile-towards a more sensitive profile-was tested by a
paired comparison in one sample. The results showed this
indeed to be the case (Figure 3). This was later confirmed in
two additional samples.
In 24 out of 30 samples the percentage of leukaemic cells
was > 80% at the start of culture, that is after the
Dynabeads procedure. Two (9%) out of these 24 samples,
both from patients with relapsed pre-B-ALL, showed a
decrease below 70% (62% and 49%) leukaemic cells after
culture. This frequency of 9% is similar to that of 13% in
samples not exposed to Dynabeads, as mentioned above. The
Dynabeads procedure did not have a significant adverse
effect on the control cell viability in drug-free wells after 4
days of culture (mean 54.8%, s.d. 18.4%), as compared with
the control cell viability in the 106 untreated ALL samples
not exposed to Dynabeads (mean 63.0%, s.d. 28.9%).
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Figure 3 Influence of the removal of mononuclear cells con-
taminating an ALL sample, using immunomagnetic beads, on
cellular drug resistance. Drug concentrations increase from A to
F (Materials and methods). The part of the ALL sample not
exposed to beads contained 61% leukaemic cells after culture,
and showed a more resistant profile than the part of the ALL
sample which was exposed to beads, and which contained 96%
leukaemic cells after culture. For key, see legend to Figure 2.
Discussion
Weisenthal (1993) reported that a decrease in the percentage
ofleukaemic cells during 4 days ofculture may occur in ALL
samples. In this study we confirm this finding for untreated
childhood ALL samples. The percentage of leukaemic cells
was determined by morphology, a subjective method. How-
ever, in case of any doubt, several technicians determined the
percentage independently, and immunology was used
whenever possible. The percentages are thus the result of a
careful assessment. In 106 samples containing > 80%
leukaemic cells at the start of culture, 28% of the samples
contained <80% and 13% of the samples contained <70%
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samples were significantly more resistant to cytotoxic agents
than samples with > 80% leukaemic cells after culture. A
decrease below 70% leukemic cells, or the presence of > 30%
mononuclear non-malignant cells, thus influences the results
of the MTT assay for untreated ALL samples. This can be
explained by the fact that contaminating mononuclear cells
are more drug resistant than these ALL cells, and by the
inability of the MTT assay to discriminate between malig-
nant and non-malignant cells (Kaspers et al., 1991). An
alternative explanation is that intrinsically resistant ALL
samples tend to show a decrease in the percentage of ALL
cells. However, we did not find a significant relation between
leukaemia features, such as immunophenotype, and a
decrease in percentage of leukaemic cells below 70%.
Moreover, there was no relation between leukaemic cell
viability and in vitro drug resistance or clinical outcome.
For ALL samples with > 80% leukaemic cells at the start
of culture, the results of the MTT assay and DiSC assay are
similar (Pieters et al., 1989; Kirkpatrick et al., 1990). The
MTT assay can therefore be used to determine the drug
resistance profile of untreated ALL samples with > 80%
leukaemic cells present at the start of culture, and the results
should not be considered evaluable in the case of the
presence of <70% leukaemic cells after culture. These cau-
tionary notes also apply for other cell culture drug resistance
assays in which no distinction can be made between malig-
nant and non-malignant cells. The cut-off points of 80% and
70% might also be appropriate for relapsed ALL samples
and acute non-lymphoblastic leukaemia samples. These sam-
ples are generally not more drug sensitive than untreated
ALL samples; in fact, they are significantly more resistant to
certain drugs (Kaspers et al., 1994; Klumper et al., 1993).
Therefore, contamination with mononuclear cells is less likely
to result in a false, over-resistant drug profile than in the case
of untreated ALL samples, assuming that similar percentages
of leukaemic cells are present in these leukaemia samples.
One alternative way to determine the drug resistance
profile of samples with <80% ALL cells is the DiSC assay,
which distinguishes drug effects on malignant and non-
malignant cells (Weisenthal & Lippman, 1985). The proce-
dure of the DiSC assay is similar to that of the MTT assay
until the moment of adding MTT to the wells. In fact, it is
possible to first determine the percentage of leukaemic cells
after culture, and only then to decide to use the MTT assay,
in the case of > 70% leukaemic cells, or the DiSC assay, in
the case of <70% leukaemic cells. However, the DiSC assay
is laborious, subjective and requires skilled technicians
(Pieters, 1989; Weisenthal & Kern, 1991). Alternatively, one
may decide to use shorter drug incubation periods. However,
in that case higher drug concentrations are needed to give
significant cell kill in ALL samples (Pieters et al., 1988). Such
concentrations would far exceed clinically achievable peak
plasma levels.
Another alternative would be to remove contaminating
non-malignant cells to enable the use of the MTT assay for
samples with initially <80% leukaemic cells or even for
samples with 80-90% leukaemic cells. A marked part of
these latter samples will show a decrease below 70%
leukaemic cells after culture. We investigated the removal of
mononuclear cells by immunomagnetic Dynabeads. These
magnetic beads have been used for purging (Shimazaki et al.,
1988; Gruhn et al., 1991), T-cell depletion of bone marrow
grafts (Vartdal et al., 1987), removal of leucocytes from renal
carincomas prior to chromosome studies (Linehan et al.,
1989) and purifying ALL samples by removing T-
lymphocytes and monocytes for proliferation studies
(Skj0nsberg et al., 1991). In the present study it appeared to
be possible to increase the percentage of leukaemic cells to
> 80% in 17 out of 22 ALL samples by Dynabeads. The
mean increase of the percentage of leukaemic cells after the
Dynabeads procedure was 15%. The mean recovery of viable
leukaemic cells was ± 80%, i.e. 20% of the cells were lost.
The procedure with Dynabeads did not alter the drug resis-
tance profile of the leukaemic cells and had no adverse effect
on the success rate of the MTT assay as compared with
normally processed samples. It even diminished the number
of dead cells in the sample. In our laboratory, we now use
Dynabeads in 15-20% of all samples received for drug
resistance testing. Criteria to use beads are the presence of at
least 5 x 106 leukaemic cells and the presence of > 10%
potentially removable contaminating cells. In our experience,
the use of beads increases the percentage of samples with
evaluable MTT assay results from 70 to 80%. These criteria
and the effect on the evaluability rate of the MTT assay may
differ between laboratories, and for instance largely depend
on the type of malignant samples tested.
We conclude that a decrease in the percentage of
leukaemic cells can occur during the culture of untreated
childhood ALL samples. This decrease should be monitored
if a sample is studied using the MTT assay or a similar assay,
because the results are significantly influenced in case of a
decrease below 70% leukaemic cells after culture. Removal of
contaminating mononuclear cells is feasible using
immunomagnetic Dynabeads, without an adverse effect on
the leukaemic cells itself. Such a removal will increase the
number of leukaemia samples which can be evaluated for
cellular drug resistance using the MTT assay. This study does
not answer the question whether this approach provides
more reliable results for individual cases than the DiSC
assay.
Some of the samples included in this study were tested in connection
with our studies on cellular drug resistance in childhood leukaemia
in cooperation with the German ALL-BFM Relapse Group (Profes-
sor G. Henze), the German CoALL Group (Professor G.E. Janka-
Schaub), and the Dutch Childhood Leukemia Study Group
(DCLSG, Dr A. Van Der Does-Van Den Berg, Dr E.R. Van Wer-
ing, Professor W.A. Kamps). Board members of the DCLSG are H.
Van Den Berg, M.V.A. Bruin, J.P.M. Bokkerink, P.J. Van Dijken,
K. Hahlen, W.A. Kamps, F.A.E. Nabben, A. Postma, J.A. Ram-
meloo, I.M. Risseeuw-Appel, A.Y.N. Schouten-Van Meeteren,
G.A.M. De Vaan, E. Th. Van 't Veer-Korthof, A.J.P. Veerman, M.
Van Weel-Sipman and R.S. Weening.
This study was supported by the Dutch Cancer Society (IKA
89-06) and by the project VONK (VU Onderzoek Naar Kinder-
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